Potential advantages of CD1-restricted T cell immunotherapy in cancer

Research output: Contribution to journalArticlepeer-review


Adoptive cell therapy (ACT) using tumor-specific “conventional” MHC-restricted T cells obtained from tumor-infiltrating lymphocytes, or derived ex vivo by either antigen-specific expansion or genetic engineering of polyclonal T cell populations, shows great promise for cancer treatment. However, the wide applicability of this therapy finds limits in the high polymorphism of MHC molecules that restricts the use in the autologous context. CD1 antigen presenting molecules are nonpolymorphic and specialized for lipid antigen presentation to T cells. They are often expressed on malignant cells and, therefore, may represent an attractive target for ACT. We provide a brief overview of the CD1-resticted T cell response in tumor immunity and we discuss the pros and cons of ACT approaches based on unconventional CD1-restricted T cells. © 2018 Elsevier Ltd
Original languageEnglish
Pages (from-to)200-208
Number of pages9
JournalMolecular Immunology
Publication statusPublished - 2018


Dive into the research topics of 'Potential advantages of CD1-restricted T cell immunotherapy in cancer'. Together they form a unique fingerprint.

Cite this